e-ISSN 2148-0532 DOI 10.54233 Open Access · CC BY-NC-SA 4.0 Türkçe
Endoüroloji Bülteni — Endourology Bulletin Submit Manuscript
Original Article Open Access

Relationship of Muscle Mass Based on Psoas Muscle Index and Skeletal Muscle Index with Recurrence and Mortality Risk in Localized Renal Cell Carcinoma: A Comprehensive

Lokalize Renal Hücreli Karsinomu Olan Hastalarda Psoas Kas İndeksi ve İskelet Kas İndeksine Dayalı Kas Kütlesinin Nüks ve Mortalite Riski ile İlişkisi: Kapsamlı Bir Retrospektif

Author information
  1. University of Health Sciences, İzmir Tepecik Health Research Center, Department of Surgical Medical Sciences, The Department of Urology
  2. Bitlis State Hospitali Urology
  3. Izmir Katip Celebi University, Katip Çelebi Application and Research Center
  4. University of Health Sciences, İstanbul Bakırköy Dr. Sadi Konuk Training Research Center, Department of Surgical Medical Sciences, The Department of Urology
  5. University of Health Sciences, İzmir Tepecik Health Research Center
Issue
Volume 17 · Issue 3
Pages
119-131
Published
September 30, 2025
DOI
https://doi.org/10.54233/endourolbull-1704160 (opens in a new tab)

Abstract

Objective: We aimed to determine the relationship between the Psoas Muscle Index (PMI) and Skeletal Muscle Index (SMI) and the risk of recurrence and mortality in patients with localized Renal Cell Carcinoma (RCC).

Material: and Methods: SMI and PMI values were obtained from non-contrast computed tomography (NCCT) measurements on slices at the L3 level, normalized by height. Available survival data, including overall survival (OS) and recurrence-free survival (RFS), were collected at postoperative follow-up. Disease recurrence was defined as radiological evidence of disease on computed tomography (CT), magnetic resonance imaging, or bone scan.

Results: In the ROC analysis, the optimal cut-off value for PMI was ≤ 5.1 cm²/m² and ≤ 3.1 cm²/m² in male and female patients, while the cut-off value for SMI was ≤ 44 cm²/m² and ≤ 30 cm²/m² in male and female patients. In multivariate analyses, female gender, recurrence, clinical T stage ≥ T3b, pathological T stage ≥T3b, and sarcopenia according to PMI and SMI were independent predictors of worse OS and RFS (p < 0.001). In Kaplan-Meier analysis, OS in patients with and without sarcopenia was 74 vs 85 months (p < 0.001), respectively. RFS were shorter in patients with sarcopenia (PMI: 76 vs 84, SMI: 74 vs 85 months, both p < 0.001)

Conclusion: In patients with localized RCC, sarcopenia was associated with earlier recurrence, shorter OS, and RFS. Patients with sarcopenia had a worse prognosis in preoperative staging.

More From This Issue